Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences

Pasadena. CA | Posted on August 18th, 2020

The Digital International Liver Congress - The Annual Meeting of the European Association for the Study of the Liver (EASL) – August 27-29, 2020

Title: Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
Authors: Edward Gane, et al.
Type: Oral Presentation
Date and Time: August 28, 2020 at 13:30 CEST
European Society of Cardiology (ESC) Congress 2020 – August 29 - September 1, 2020

Title: RNA Interference Targeting Apolipoprotein C-3 with ARO-APOC3 in Healthy Volunteers Mimics Lipid and Lipoprotein Findings Seen in Subjects With Inherited Apolipoprotein C-3 Deficiency
Authors: Christian Schwabe, et al.
Presenter: Christie M. Ballantyne
Type: Oral Presentation
Date and Time: August 31, 2020 at 10:50 CEST
Title: RNAi Inhibition of Angiopoietin-like Protein 3 (ANGPTL3) with ARO-ANG3 Mimics the Lipid and Lipoprotein Profile of Familial Combined Hypolipidemia
Authors: Gerald F. Watts, et al.
Type: Oral Presentation
Date and Time: August 31, 2020 at 11:00 CEST
A copy of the presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Graphene key for novel hardware security May 10th, 2021

With a zap of light, system switches objects' colors and patterns: "Programmable matter" technique could enable product designers to churn out prototypes with ease May 6th, 2021

Polarization-sensitive photodetection using 2D/3D perovskite heterostructure crystal May 4th, 2021

Polarization-sensitive photodetection using 2D/3D perovskite heterostructure crystal May 4th, 2021

Possible Futures

Graphene key for novel hardware security May 10th, 2021

With a zap of light, system switches objects' colors and patterns: "Programmable matter" technique could enable product designers to churn out prototypes with ease May 6th, 2021

Polarization-sensitive photodetection using 2D/3D perovskite heterostructure crystal May 4th, 2021

Polarization-sensitive photodetection using 2D/3D perovskite heterostructure crystal May 4th, 2021

Nanomedicine

World's first fiber-optic ultrasonic imaging probe for future nanoscale disease diagnostics April 30th, 2021

Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease April 28th, 2021

Silver ions hurry up, then wait as they disperse: Rice chemists show ions’ staged release from gold-silver nanoparticles could be useful property April 23rd, 2021

Synthetic gelatin-like material mimics lobster underbelly’s stretch and strength: The membrane’s structure could provide a blueprint for robust artificial tissues April 23rd, 2021

Announcements

Graphene key for novel hardware security May 10th, 2021

With a zap of light, system switches objects' colors and patterns: "Programmable matter" technique could enable product designers to churn out prototypes with ease May 6th, 2021

Polarization-sensitive photodetection using 2D/3D perovskite heterostructure crystal May 4th, 2021

Polarization-sensitive photodetection using 2D/3D perovskite heterostructure crystal May 4th, 2021

Events/Classes

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

CEA-Leti Envisions Widespread Use of LiDAR Systems Based on Integrated Optical Phased Arrays (OPAs): OPAs with Solid-State Beam Steering Can Reduce the Cost and Size of LiDAR Systems & Improve Performance; Results Reported at Photonics West 2021 March 9th, 2021

CEA-Leti Announces 16 Papers to Be Presented At Photonics West 2021 and a Virtual Workshop on March 25 March 3rd, 2021

Nanobiotechnology

Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease April 28th, 2021

Synthetic gelatin-like material mimics lobster underbelly’s stretch and strength: The membrane’s structure could provide a blueprint for robust artificial tissues April 23rd, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project